Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04050124 · ClinicalTrials.gov registry record · NA
Impact of Prisma on Donor Site Pain
A NA study of Skin Graft Disorder and Donor Site Complication, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04050124: Completed NA study of Skin Graft Disorder and Donor Site Complication, sponsored by NYU Langone Health.
NCT04050124 is a NA study of Skin Graft Disorder and Donor Site Complication that has completed, run by NYU Langone Health. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04050124, a NA study of Skin Graft Disorder and Donor Site Complication, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the feasibility of evaluating the use of a composite collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
Primary Outcome
Pain score is measured using a VAS ranging from 0-10, where 0 = no pain and 10 = unbearable pain. Participants select the number that best reflects their current status. The total score is the numerical response; lower scores indicate lower pain.
Conditions Studied
Interventions
- DEVICE Promogran Prisma
- DEVICE Standard of care (SOC) dressings
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2021-11-29 |
| Phase | NA |
What the finished NCT04050124 record still lists
NCT04050124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Skin Graft Disorder appearing as the primary indexed condition, and to 2 interventions - of which Promogran Prisma is the first listed.
NCT04050124 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04050124 about?
NCT04050124 is a clinical study titled "Impact of Prisma on Donor Site Pain". The purpose of this study is to assess the feasibility of evaluating the use of a composite collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
What is the current status of trial NCT04050124?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2019-11-07. Estimated completion is 2021-11-29.
What conditions does trial NCT04050124 study?
This clinical trial studies the following conditions: Skin Graft Disorder, Donor Site Complication.
What interventions are being tested in trial NCT04050124?
The interventions under investigation include: Promogran Prisma (DEVICE), Standard of care (SOC) dressings (DEVICE).
Who is sponsoring clinical trial NCT04050124?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04050124 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04050124's enrollment target sits among peer trials
17 1871st of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI